Jeffrey W. Albers, Director at Kymera Therapeutics, Inc. (KYMR), sold 9,385 shares at $39.05 ($366K) on 2024-02-21, disclosed to the SEC on 2024-02-21.
Scheduled sale ($366k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $39.07 | 615 | $24K | 6.6% |
| 2 | $39.05 | 4,385 | $171K | 46.7% |
| 3 | $39.05 | 4,385 | $171K | 46.7% |
| Total | $39.05 avg | 9,385 | $366K | 100% |
| Filing → |
| KYMR | SELL | 2025-10-14 | $296K | — | Filing → |
| KYMR | SELL | 2025-06-03 | $311K | — | Filing → |
| BPMC | SELL | 2025-05-29 | $572K | — | Filing → |